We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with nonvisceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM clinical trial have demonstrated that treatment with the androgen receptor inhibitor enzalutamide (Xtandi) resulted in significant improvements in outcomes for men with mCRPC. This blog post discusses the efficacy of enzalutamide among men from the AFFIRM trial who had visceral disease. Men who were in [...]
Malecare Releases A Symptom, Side Effect and Quality of Life Reporting App That Can Go Directly To Your Doctor
Today, Malecare has released their first mobile app, Cancer Graph. Cancer Graph is a symptom and side effect reporting tool as well as a quality of life reporting tool. Cancer graph will allow you to keep track of all of your symptoms and side effects from any cancer you might have as well as report them, real time directly to your doctors. By using Cancer Graph you will never forget to share with your doctor any issues you face, as well as the time that you experience the symptom or side effect. Your doctor will be able to know when [...]
Malecare Founder and Executive Director Darryl Mittendorf Recognized For His Major Contributions To The Prostate Cancer Community By PCRI
Malecare's Founder and Executive Director Darryl Mitteldorf was this years PCRI winner of the Harry Pinchot Award. He is long deserving of this award. I would like to thank Darryl for his years and years of work and PCRI for recognizing his major contributions to our prostate cancer community. Thank you Darryl A video of Darryl Mitteldorf accepting the Prostate Cancer Research Institute (PCRI) 2016 Harry Pinchot Award https://youtu.be/aBo3N59oIvo
Clinical Trial Results, Both Negative and Positive, Will Now Have To Be Reported In A Timely Manner!
Clinical trials are the main stream of developing and then getting necessary approvals for drugs to be able to make it to market. Drug companies, like every other company and every individual want only to have successes. We all also have egos and when there is a failure we often prefer to bury that information so that it doesn’t reflect poorly on us. This is human nature and it can serve as an economic driver for drug companies. When clinical trials do fail this information is most often not reported. Also, sometimes when trials do succeed the information, for various [...]